Technical Trend Shift and Price Movement
The stock closed at ₹228.00 on 10 Apr 2026, down 0.96% from the previous close of ₹230.20. Intraday price action showed a high of ₹230.80 and a low of ₹225.95, indicating a modest trading range but with a downward bias. The 52-week high stands at ₹305.95, while the 52-week low is ₹210.60, placing the current price closer to the lower end of its annual range.
The technical trend has deteriorated from mildly bearish to outright bearish, signalling increased selling pressure. This shift is corroborated by the daily moving averages, which remain bearish, suggesting that short-term momentum is weak and the stock is trading below key average price levels.
MACD and Momentum Indicators
The Moving Average Convergence Divergence (MACD) indicator presents a mixed but predominantly negative outlook. On a weekly basis, the MACD is bearish, indicating that the short-term momentum is declining relative to the longer-term trend. The monthly MACD remains mildly bearish, reflecting a slower but persistent downtrend in momentum over a longer horizon.
Such MACD readings imply that the stock is likely to face continued resistance in mounting a sustained rally, as the momentum oscillators have not yet signalled a reversal or recovery.
RSI and Overbought/Oversold Conditions
The Relative Strength Index (RSI) on both weekly and monthly charts currently shows no clear signal, hovering in a neutral zone. This suggests that the stock is neither overbought nor oversold at present, leaving room for further downside or sideways consolidation before a definitive momentum shift might occur.
Investors should monitor RSI closely for any move below 30, which would indicate oversold conditions and potential for a bounce, or above 70, signalling overbought levels and possible pullback.
Bollinger Bands and Volatility
Bollinger Bands on weekly and monthly timeframes are mildly bearish, reflecting a slight expansion in volatility with a downward bias. The stock price is trending towards the lower band, which often acts as a support level but can also indicate increasing selling pressure if breached decisively.
This mild bearishness in volatility measures aligns with the overall technical deterioration and suggests that price swings may become more pronounced in the near term.
Handpicked from 50, scrutinized by experts – Our recent selection, this Mid Cap from Bank - Public, is already delivering results. Don't miss next month's pick!
- - Expert-scrutinized selection
- - Already delivering results
- - Monthly focused approach
Moving Averages and KST Indicator
Daily moving averages are firmly bearish, with the stock trading below its short-term and medium-term averages. This confirms the downward momentum and suggests that any rallies are likely to encounter resistance near these averages.
The Know Sure Thing (KST) indicator, a momentum oscillator, is bearish on a weekly basis and mildly bearish monthly. This further reinforces the negative momentum outlook, indicating that the stock’s price action is unlikely to reverse in the short term without significant positive catalysts.
Volume and Dow Theory Signals
On-balance volume (OBV) is mildly bearish weekly, signalling that volume trends are not supporting price advances. The lack of strong volume backing for any upward moves suggests that sellers currently dominate the market sentiment.
Dow Theory assessments show a mildly bearish weekly trend and no clear monthly trend, indicating uncertainty in the broader directional movement but with a bias towards downside risk.
Comparative Returns and Market Context
Examining Artemis Medicare’s returns relative to the Sensex reveals a mixed performance. Over the past week, the stock gained 1.92%, lagging behind the Sensex’s 4.52% rise. Over one month, Artemis inched up 0.51% while the Sensex declined 1.20%, showing some relative resilience.
However, year-to-date returns for Artemis are down 15.87%, underperforming the Sensex’s -10.08%. Over the last year, the stock has declined 17.51%, contrasting with the Sensex’s positive 3.77% gain. This underperformance highlights sector-specific or company-specific challenges amid broader market strength.
Longer-term returns remain impressive, with a three-year gain of 225.57% compared to the Sensex’s 28.08%, and a five-year gain of 942.05% versus the Sensex’s 54.53%. These figures underscore Artemis Medicare’s strong historical growth trajectory despite recent technical setbacks.
Holding Artemis Medicare Services Ltd from Hospital? See if there's a smarter choice! SwitchER compares it with peers and suggests superior options across market caps and sectors!
- - Peer comparison ready
- - Superior options identified
- - Cross market-cap analysis
Mojo Score and Analyst Ratings
Artemis Medicare currently holds a Mojo Score of 43.0, categorised as a Sell rating. This represents a downgrade from its previous Hold grade as of 2 Mar 2026, reflecting deteriorating technical and fundamental signals. The small-cap classification adds an element of volatility and risk, which investors should weigh carefully.
The downgrade aligns with the technical indicators’ bearish signals and the recent price underperformance relative to benchmarks. Investors should be cautious and consider the potential for further downside or consolidation before any recovery.
Outlook and Investor Considerations
Given the current technical landscape, Artemis Medicare Services Ltd faces headwinds in the near term. The convergence of bearish MACD, moving averages, and KST indicators, combined with neutral RSI and mild bearish Bollinger Bands, suggests a cautious stance.
Investors should monitor key support levels near ₹210.60, the 52-week low, and watch for any shifts in volume or momentum that could signal a reversal. Until then, the technical outlook remains unfavourable, and the stock may continue to underperform relative to broader indices and sector peers.
Long-term investors may find value in the company’s strong historical returns, but short-term traders should heed the bearish momentum and consider risk management strategies accordingly.
Summary
Artemis Medicare Services Ltd’s technical parameters have shifted decisively towards bearishness, with multiple indicators confirming weakening momentum. The downgrade in Mojo Grade to Sell and the stock’s underperformance relative to the Sensex reinforce a cautious investment approach. While long-term fundamentals remain robust, the near-term technical outlook suggests limited upside and potential for further declines.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
